
FDA Proposes Rule to Allow NAC as a Dietary Supplement Ingredient
Key Takeaways
- A new 21 CFR 190.1 would enumerate ingredients not excluded from the supplement definition, initially listing NAC and reserving space for future ingredients added via the same authority.
- Historical exclusion hinged on NAC’s 1963 drug approval and lack of evidence for pre-1963 food/supplement marketing, despite widespread supplement-labeled sales for over 30 years.
The proposal would reverse FDA’s position that N-acetyl-L-cysteine is excluded from the supplement definition and would replace the agency’s enforcement discretion policy if finalized.
FDA on November 16 announced a proposed rule that would reverse the exclusion of N-acetyl-L-cysteine (NAC) from the dietary supplement definition, according to an agency constituent update.1 If finalized, NAC-containing products could be marketed as dietary supplements as long as they otherwise comply with the Federal Food, Drug, and Cosmetic (FD&C) Act. A pre-publication copy of the rule is scheduled to appear in the Federal Register on November 17.2
What Would the Proposed Rule Do?
The draft would create a new regulation, 21 CFR 190.1, listing ingredients not excluded from the supplement definition. NAC would be the first entry, with a second paragraph reserved for future additions. The rule would also provide that adding NAC to a supplement is not a prohibited act under section 301(ll) of the FD&C Act. FDA described the action as its first use of its rulemaking authority under the definition’s exclusion provision.
NAC products would stay subject to existing supplement requirements, including current good manufacturing practice regulations, and adulterated or misbranded products could face enforcement action. FDA proposed that a final rule take effect immediately upon publication.
Why Was NAC Excluded?
FDA said NAC was approved as a drug in 1963, before the earliest marketing of NAC as a supplement it is aware of, which kept it outside the definition under the exclusion clause. The agency said it knows of no evidence that NAC was sold as a food or supplement before that approval and asked for any. FDA also noted that NAC-containing products labeled as supplements have been sold in the US for more than 30 years.
In March 2022, FDA rejected requests from the Council for Responsible Nutrition and the Natural Products Association to change that position, though it said its review thus far showed no safety concerns and that it was considering rulemaking.3
How Has FDA Handled NAC Products Until Now?
In August 2022, FDA issued guidance stating it intended to exercise enforcement discretion for certain NAC products labeled as supplements that would otherwise be lawfully marketed and are not in violation of the FD&C Act.4 The policy was to last until FDA completed rulemaking or denied the rulemaking request in the petition. FDA said it intends to withdraw the guidance if the rule is finalized.
What Did FDA’s Safety Review Find?
FDA said its systematic review of orally ingested NAC, which underwent external peer review, drew on 41 high-confidence studies, including doses up to 9,000 mg per day and durations up to 3 years. It concluded a “minimal” level of concern. Reported adverse events were mostly gastrointestinal, such as nausea and pain, and only one study was highlighted as showing a statistically significant increase in nausea. FDA said common supplement servings of 600, 1,000, and 1,200 mg per day fall within the studied doses. The constituent update said the review found no safety concerns.
What About Drug Development and Costs?
FDA said it has no reason to expect an effect on NAC drug development, citing more than 30 years of supplement sales alongside approved NAC drugs, at least 19 generic drug applications, and 832 clinical trials. It estimated annualized costs of about $99 to $121, mainly for industry to read the rule, and did not estimate benefits. It expects the rule to count as deregulatory under Executive Order 14192.
Comments are due 60 days after publication in Docket FDA-2025-N-2699. Overall, FDA is seeking input on the pre-1963 marketing evidence, the drug development effect, the effective date, and its cost estimates.
References
- US Food and Drug Administration. FDA issues proposed rule on NAC products as dietary supplements. November 16, 2026. Accessed November 16, 2026.
https://www.fda.gov/food/hfp-constituent-updates/fda-issues-proposed-rule-nac-products-dietary-supplements - US Food and Drug Administration. Rulemaking to provide that N-acetyl-L-cysteine is not excluded from the dietary supplement definition. Proposed rule. Docket FDA-2025-N-2699. Scheduled for publication in the Federal Register November 17, 2026. Accessed November 16, 2026.
https://www.federalregister.gov/d/2026-23351 - US Food and Drug Administration. Response to citizen petitions, Dockets FDA-2021-P-0523 and FDA-2021-P-0938. March 31, 2022. Accessed November 16, 2026.
https://www.regulations.gov/document/FDA-2021-P-0938-0030 - US Food and Drug Administration. Guidance for industry: policy regarding N-acetyl-L-cysteine. Docket FDA-2022-D-0490. August 2022. Accessed November 16, 2026.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-regarding-n-acetyl-l-cysteine - US Food and Drug Administration. FDA releases final guidance on enforcement discretion for certain NAC products. Constituent update. August 2022. Accessed November 16, 2026.
https://www.fda.gov/food/hfp-constituent-updates/fda-releases-final-guidance-enforcement-discretion-certain-nac-products
Related to this article








